Pharmaceutical Grade QSC Tirzepatide - GLP-1/GIP Receptor Agonist Supplier

QSC Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research applications. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.

The molecular mechanism of QSC Tirzepatide involves preferential binding to GIP receptors while maintaining significant activity at GLP-1 receptors. This unique dual agonist profile results in enhanced glycemic control, making it a valuable compound for metabolic research.

For research use only. Not for human consumption. Proper storage and handling procedures must be followed to maintain compound stability and integrity.

Our production facility maintains strict quality control measures to ensure batch-to-batch consistency. Custom synthesis services are available for specific research requirements.